Salpetriere hospital experience with biochemotherapy in metastatic melanoma

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Antoine, E G ^a   Benhammouda, A ^a   Bernard, A ^a   Youssef, A ^a   Mortier, N ^a   Gozy, M ^a   Nizri, D ^a   Auclerc, G ^a   Rocher, M A ^a   Soubrane, C L ^a   Weil, M ^a   Khayat, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Biochemotherapy; Cisplatin; Interleukin 2

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; FOTEMUSTINE; LOMUSTINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2; SEMUSTINE; TAMOXIFEN; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; INTERLEUKIN 2; RECOMBINANT PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; ADOLESCENT; IMMUNOTHERAPY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; RECOMBINANT PROTEINS; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 18544395504     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wingo P, Tong T, Bolden S. Cancer statistics. Ca Cancer J Clin 1995;45:8-30.
2. Anderson C, Buzaid A, Legha S. Systemic treatments for advanced cutaneous melanoma. Oncology 1995;9:1149-1158.
3. Kirkwood J, Agarwala S. Systemic cytotoxic and biologic therapy of melanoma. PPO Updates 1993;7:1-16.
4. Rosenberg SA, Lòtze MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1990;210:474.
5. Dutcher JP, Creekmore S, Weiss GR et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989;7:477-485.
6. Khayat D, Borel C, Tourani JM et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alpha-2a for metastatic melanoma. J Clin Oncol 1993;11:2173-2180.
7. Demchak P, Mier J, Robert N et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 1991;9:1821-1830.
8. Flaherty L, Robinson W, Redman B et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic melanoma. Cancer 1993;71: 3520-3525.
9. Atkins M, O'Boyle K, Sosman J et al. Multiinstitutional phase II trial of intensive combination chemimmunotherapy for metastatic melanoma. J Clin Oncol 1994;12:1553-1560.
10. Blair S, Flaherty L, Valdivieso M et al. A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 1990;65:2471.
11. Richards J, Mehta N, Schroeder L et al. Sequential chemotherapy/ immunotherapy for metastatic melanoma. Proceedings of ASCO 1992;11:346.
12. Dorval T, Negrier S, Chevreau C et al. Results of a French multicentric randomized trial of chemoimmunotherapy (cisplatin (p), IL-2 (proleukin), with or without IFN (roferon)) in metastatic malignant melanoma. Proceedings of ASCO 1994;13:1347a.
13. Keilholz U. Immunotherapy and chemoimmunotherapy of melanoma. Presented at the Sixth International Congress on Anti-Cancer Treatment; Paris, France.
14. Legha S, Buzaid A, Ring S et al. Improved results of treatments of metastatic melanoma with combined use of biotherapy and chemotherapy. Proceedings of ASCO 1994;13:394.
15. Legha SS, Ring S, Bedikian A et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α. Ann Oncol 1996;7:827-835.
16. Legha SS, Ring S, Eton O et al. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center Experience. Cancer J Sci Am 1997;3[suppl 1]:S9-S15.
17. Sodhi A, Pai K, Singh R et al. Activation of human NK cells and monocytes with cisplatin in vitro. Int J Immunopharmacol 1990; 12:893-898.
18. Sodhi A, Basu S. Role of human blood monocytes in up-regulation of lymphokine (interleukin-2)-activated killer cell activity with cisplatin and FK-565. Nat Immun 1992;11:105-116.
19. Tsuda H, Kitahashi S, Umesaki N et al. Abrogation of suppressor cell activity by cis-diaminedichloroplatinum treatment using therapeutic doses in ovarian cancer patients. Gynecol Oncol 1994;52: 218-221.
20. Bernsen M, van Barlingen H, van der Velden A et al. Dualistic effects of cis-diaminedichloro-platinum on the antitumor efficacy of subsequendy applied recombinant interleukin-2 therapy: a tumor-dependent phenomenon. Int J Cancer 1993;54:513-517.
21. Anderson CM, Buzaid AC, Ali-Osman F et al. Biochemotherapy in the treatment of advanced melanoma: clinical results and potential mechanisms of anticancer activity. Progress in Anti-Cancer Chemotherapy; in press.
22. Walder S, Schwartz E. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990;50:3473-3486.
23. Chang M-J, Modzelewski R, Russell D et al. Interleukin-1 alpha and gamma-interferon induction of nitric oxide production from murine tumor-derived endothelial cells. Cancer Res 1996;56:886-891.